We recently published an article entitled Why These 10 Stocks Jumped Yesterday. In this article, we are going to take a look at where Centessa Pharmaceuticals PLC (NASDAQ:CNTA) stands against the other stocks that jumped yesterday.
Broader indices haven't been performing very well since the Fed's not so surprise revelation about the number of expected cuts in 2025. Nevertheless, several stocks on Thursday posted notable gains.
On Thursday, Centessa Pharmaceuticals (CNTA) finished the week stronger, with its share price posting a 6.3 percent increase to close at $17.55 apiece.
According to news reports, analysts were bullish on the company’s stock price, receiving a higher price target from hedge funds.
According to Leerink Partners, it upgraded its price target for the company to $24 apiece and maintained an “outperform” rating, reflecting an optimistic view on the company's ORX750 program, for the treatment of narcolepsy.
Leerink Partners also raised its sales projections for Centessa's total sales by 4 percent to $1.3 billion in 2032, as well as its earnings per share by 18 percent to $5.21 from $4.42.
Centessa similarly received a higher price target and a “buy” rating from financial services giant Guggenheim to $28, reflecting a positive outlook for the company.
Overall CNTA ranks 8th on our list of the stocks that jumped yesterday. While we acknowledge the potential of CNTA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CNTA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。